Osteoporosis patient

Preotact® - treatment for osteoporosis patients

An osteoporosis patient experiences low bone mass, structural deterioration of bone and increased risk of fracture. Osteoporosis is most common in women after menopause this is also known as postmenopausal osteoporosis. Due to the risk of bone fracture osteoporosis can affect life expectancy and quality of life of the osteoporosis patient.

Preotact® is a full-length parathyroid hormone (PTH) therapy that can reduce the risk of bone fracture for an osteoporosis patient suffering from postmenopausal osteoporosis. The parathyroid hormone can stimulate bone formation and increase trabecular bone density, which can improve bone microarchitecture and restore bone quality and quantity of the osteoporosis patient.

Log in to learn more about osteoporosis patient treatment with Preotact®

Nycomed

Nycomed is a European pharmaceutical company that has over 20 years’ experience of working with osteoporosis. Nycomed operates throughout Europe and in fast-growing markets in Latin America, Russia/CIS and Asia-Pacific.

Nycomed provides medicines and products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets. Offering a broad portfolio of products in a wide range of therapeutic areas, particularly cardiology, gastroenterology, osteoporosis, respiratory, and pain and tissue management.